Uncovering the genetics of systemic lupus erythematosus: Implications for therapy

American Journal of PharmacoGenomics

Volumn 3, Issue 3, 2003, Pages 193-202

  Kyttaris, Vasileios C ^a,b   Tsokos, George C ^a,b  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 2;

CLINICAL FEATURE; COHORT ANALYSIS; COMPLEMENT GENE; GENE; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENE THERAPY; GENETIC ANALYSIS; GENOME; HEREDITY; HUMAN; IMMUNOCOMPETENT CELL; LINKAGE ANALYSIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR GENETICS; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; VALIDATION PROCESS;

ANIMALS; GENE THERAPY; HUMANS; LINKAGE (GENETICS); LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 0037668666     PISSN: 11752203     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129785-200303030-00005     Document Type: Review

References (116)

1. Tsokos GC, Boumpas DT. Systemic lupus erythematosus. In: Theofilopoulos A, Bona C, editors. Molecular pathology of autoimmunity. 2nd ed. New York: Taylor and Francis, 2002: 261-87
2. Kammer GM, Tsokos GC. Molecular aberrations in human lupus. Mol Med Today 2000; 6: 418-24
3. Mackay I, Rosen F. Advances in immunology: complement, second of two parts. N Engl J Med 2001; 344: 1140-4
4. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41: 778-99
5. Jonsson H, Nived O, Sturfelt G, et al. Estimating the incidence of systemic lupus erythematosus in a defined population using multiple sources of retrieval. Br J Rheumatol 1990; 29: 185-8
6. McCarty DJ, Manzi S, Medsger Jr TA, et al. Incidence of systemic lupus erythematosus: race and gender differences. Arthritis Rheum 1995; 38: 1260-70
7. Lahita RG. The role of sex hormones in systemic lupus erythematosus. Curr Opin Rheumatol 1999; 11: 352-6
8. Hochberg MC. The incidence of systemic lupus erythematosus in Baltimore, Maryland, 1970-1977. Arthritis Rheum 1985; 28: 80-6
9. Ward MM, Studenski S. Clinical manifestations of systemic lupus erythematosus: identification of racial and socioeconomic influences. Arch Intern Med 1990; 150: 849-53
10. Uramoto KM, Michet Jr CJ, Thumboo J, et al. Trends in the incidence and mortality of systemic lupus erythematosus. Arthritis Rheum 1999; 42: 46-50
11. Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993; 72: 113-24
12. Liossis SN, Tsokos GC. Pathogenesis of rheumatic diseases: systemic lupus erythematosus. In: Tsokos GC, editor. Principles of molecular rheumatology. Totowa (NJ): Humana Press, 2000: 311-23
13. Arnett FC, Reveille JD, Wilson RW, et al. Systemic lupus erythematosus: current state of the genetic hypothesis. Semin Arthritis Rheum 1984; 14: 24-35
14. Lawrence JS, Martins CL, Drake GL. A family survey of lupus erythematosus: heritability. J Rheumatol 1987; 14: 913-21
15. Dcapen D, Escalante A, Weinrib L, et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 1992; 35: 311-8
16. Cutolo M, Sulli A, Seriolo B, et al. Estrogens, the immune response and autoimmunity. Clin Exp Rheumatol 1995; 13: 217-26
17. Sontheimer RD, Gilliam JN. Systemic lupus erythematosus and the skin. In: Lahita RG, editor. Systemic lupus erythematosus. New York: Churchill and Livingstone, 1992
18. Cooper GS, Dooley MA, Treadwell EL, et al. Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus. Arthritis Rheum 1998; 41: 1714-24
19. Ghaussy NO, Sibbitt Jr WL, Qualls CR. Cigarette smoking, alcohol consumption, and the risk of systemic lupus erythematosus: a case-control study. J Rheumatol 2001; 28: 2449-53
20. James JA, Kaufman KM, Farris AD, et al. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997; 100: 3019-26
21. Horwitz DA, Stohl W, Gray JD. T lymphocytes, natural killer cells, cytokines, and immune regulation. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. Baltimore (MD): Lippincott Williams and Wilkins, 1997: 155-94
22. Tsokos GC. Overview of cellular immune function in systemic lupus erythematosus. In: Lahita RG, editor. Systemic lupus erythematosus. New York: Academic Press, 1999: 17-54
23. Horwitz DA, Gray JD, Ohtsuka K, et al. The immunoregulatory effects of NK cells: the role of TGF- and implications for autoimmunity. Immunol Today 1997; 18: 538-42
24. Stohl W, Elliott JE, Hamilton AS, et al. Impaired recovery and cytolytic function of CD56+ T and non-T cells in systemic lupus erythematosus following in vitro polyclonal T cell stimulation: studies in unselected patients and monozygotic disease-discordant twins. Arthritis Rheum 1996; 39: 1840-51
25. Tsokos GC, Liossis S-NC. Immune cell signaling defects in lupus: activation, ancrgy and death. Immunol Today 1999; 20: 119-24
26. Takeuchi T, Pang M, Amano K, et al. Reduced protein tyrosine phosphatase (PTPase) activity of CD45 on peripheral blood lymphocytes in patients with systemic lupus crythematosus. Clin Exp Immunol 1997; 109: 20-6
27. Liossis S-NC, Ding XZ, Dennis GJ, et al. Altered pattern of TcR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus crythematosus: deficient expression of the T cell receptor zeta chain. J Clin Invest 1998; 101: 1448-57
28. Brundula V, Rivas LJ, Blasini AM, et al. Diminished levels of T cell receptor chains in peripheral blood T lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 1908-16
29. Matache C, Stefanescu M, Onu A, et al. p561ck activity and expression in peripheral blood lymphocytes from patients with systemic lupus erythematosus. Autoimmunity 1999; 29: 111-20
30. Vassilopoulos D, Kovacs B, Tsokos GC. TCR/CD3 complex-mediated signal transduction pathway in T cells and T cell lines from patients with systemic lupus erythematosus. J Immunol 1995; 155: 2269-81
31. Mandler R, Birch RE, Polmar S, et al. Abnormal adenosine-induced immunosuppression and cAMP metabolism in T lymphocytes of patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A 1982; 79: 7542-6
32. Hasler P, Schultz LA, Kammer GM. Defective cAMP-dependent phosphorylation of intact T lymphocytes in active systemic lupus erythematosus. Proc Natl Acad Sci U S A 1990; 87: 1978-82
33. Kammer GM, Khan IU, Malemud CJ. Deficient type 1 protein kinase A isozyme activity in systemic lupus erythematosus T lymphocytes. J Clin Invest 1994; 94: 422-30
34. Mishra N, Khan IU, Tsokos GC, et al. Association of deficient type II protein kinase A activity with aberrant nuclear translocation of the RII-subunit in systemic lupus erythematosus T lymphocytes. J Immunol 2000; 165: 2830-40
35. Tada Y, Nagasawa K, Yamauchi Y, et al. A defect in the protein kinase C system in T cells from patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1991; 60: 220-31
36. Ng TT, Collins IE, Kinner SB, et al. Integrin signalling defects in T-lymphocytes in systemic lupus erythematosus. Lupus 1999; 8: 39-51
37. Deng C, Kaplan MJ, Yang J, et al. Decreased ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum 2001; 44: 397-407
38. Wong HK, Kammer GM, Dennis G, et al. Abnormal NF-κB activity in T lymphocytes from patients with systemic lupus erythematosus is associated with decreased p65-RelA protein expression. J Immunol 1999; 163: 1682-9
39. Solomou EE, Juang Y-T, Gourley MF, et al. Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J Immunol 2001; 166: 4216-22
40. Grolleau A, Kaplan MJ, Hanash SM, et al. Impaired translational response and increased protein kinase PKR expression in T cells from lupus patients. J Clin Invest 2000; 106: 1561-8
41. Gergely Jr P, Grossman C, Niland B, et al. Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum 2002; 46: 175-90
42. McDevitt HO, Bodmer WF. Histocompatibility antigens, immune responsiveness and susceptibility to disease. Am J Med 1972; 52: 1-8
43. Goldberg MA, Arnett FC, Shulman LE. Histocompatibility antigens in SLE. Arthritis Rheum 1976; 19: 129-32
44. Eroglu GE, Kohler PF. Familial systemic lupus erythematosus: the role of genetic and environmental factors. Ann Rheum Dis 2001; 61: 29-31
45. Tsao BP. An update on genetic studies of systemic lupus erythematosus. Curr Rheumatol Rep 2002; 4: 359-67
46. Schur PH. Genetics of systemic lupus erythematosus. Lupus 1995; 4: 425-37
47. Galeazzi M, Sebastiani GD, Morozzi G, et al. HLA Class II DNA Typing in a Large series of European Patients with Systemic Lupus Erythematosus. Medicine (Baltimore) 2002; 81: 169-78
48. Reveille JD, Moulds JM, Ahn C, et al. Systemic lupus erythematosus in three ethnic groups: I. the effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum 1998; 41: 1161-72
49. Schur PH, Marcus B, Awdeh Z, et al. The effect of ethnicity on major histocompatibility complex, complement allotypes and extended haplotypes in patients with systemic lupus crythcmatosus. Arthritis Rheum 1990; 33: 985-92
50. Bidwell J, Keen L, Gallagher G, et al. Cytokine gene polymorphism in human disease: on-line databases. Genes Immun 1999; 1: 3-19
51. Rudwaleit M, Tilky M, Khamashtra M, et al. Interethnic differences in the association of tumor necrosis factor promoter polymorphisms with systemic lupus erythematosus. J Rheumatol 1996; 23: 1723-8
52. Wilson AG, De Vries N, Pociot F, et al. An allelic polymorphism with the tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, DR3 alleles. J Exp Med 1993; 177: 557-60
53. Morita C, Horiuchi T, Tsukamoto H, et al. Association of tumor necrosis factor receptor type II polymorphism 196R with systemic lupus erythematosus in the Japanese: molecular and functional analysis. Arthritis Rheum 2001; 44: 2819-27
54. Wilson AG, Symons JA, McDowell TL, et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A 1997; 94: 3195-9
55. Klinman DM, Steinberg AD. Inquiry into human and murine lupus. Immunol Rev 1995; 144: 157-93
56. Jacob CO, Fronek Z, Lewis GD, et al. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci U S A 1990; 87: 1233-7
57. Pickering MC, Botto M, Taylor PR, et al. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 2000; 76: 227-324
58. Browness P, Davies KA, Norsworthy PJ, et al. Hereditary C1q deficiency and systemic lupus erythematosus. QMJ 1994; 87: 455-64
59. Howard PF, Hochberg MC, Bias WB, et al. Relationship between C4 null genes, HLA-D region antigens and genetic susceptibility to systemic lupus erythematosus in Caucasian and black Americans. Am J Med 1986; 81: 187-93
60. Davies EL, Snowden N, Hillarby MC, et al. Mannose-binding protein gene polymorphism in systemic lupus erythematosus. Arthritis Rheum 1995; 38: 110-4
61. Sullivan KE, Wooten C, Goldman D, et al. Mannose-binding protein genetic polymorphisms in black patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39: 2046-51
62. Davies EJ, Teh LS, Ordi-Ros J, et al. A dysfunctional allele of the mannosc binding protein gene associates with systemic lupus erythematosus in a Spanish population. J Rheumatol 1997; 24: 485-8
63. Salmon JE, Millard S, Schachter LA, et al. Fc gamma RIIA alleles are heritable risk for SLE nephritis in African Americans. J Clin Invest 1996; 97: 1348-54
64. Duits AJ, Bootsma H, Derksen R, et al. Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Arthritis Rheum 1995; 39: 1832-6
65. Zuniga R, Ng S, Peterson MG, et al. Low-binding alleles of Fcgamma receptor types IIA and IIIA are inherited independently and are associated with systemic lupus erythematosus in Hispanic patients. Arthritis Rheum 2001; 44: 361-7
66. Botto M, Theodoridis E, Thompson EM, et al. Fc gamma RIIa polymorphism in systemic lupus erythematosus (SLE): no association with disease. Clin Exp Immunol 1996; 104; 264-8
67. D'Alfonso S, Rampi M, Bocchio D, et al. Systemic lupus erythematosus candidate genes in the Italian population: evidence for a significant association with interleukin-10. Arthritis Rheum 2000; 43: 120-8
68. Salmon JE, Ng S, Yoo DH, et al. Altered distribution of Fcgamma receptor IIIA alleles in a cohort of Korean patients with lupus nephritis. Arthritis Rheum 1999; 42: 818-9
69. Song YW, Han CW, Kang SW, et al. Abnormal distribution of Fc gamma receptor type IIa polymorphisms in Korean patients with systemic lupus erythematosus. Arthritis Rheum 1998; 41: 421-6
70. Manger K, Repp R, Spriewald BM, et al. Fcg receptor IIa polymorphism in Caucasian patients with systemic lupus erythematosus: association with clinical symptoms. Arthritis Rheum 1998; 41: 1181-9
71. Dijstelbloem HM, Biji M, Fijnhcer R, et al. Fc gamma receptor polymorphisms in systemic lupus erythematosus: association with disease and in vivo clearance of immune complexes. Arthritis Rheum 2000; 43: 2793-800
72. Hasclcy LA, Wisnieski JJ, Denburg MR, et al. Antibodies to Clq in systemic lupus erythematosus: characteristics and relation to Fc gamma RIIA alleles. Kidney Int 1997; 52: 1375-80
73. Norsworthy P, Theodoridis E, Botto M, et al. Overrepresentation of the Fcgamma receptor type IIA R131/R131 genotype in caucasian systemic lupus erythematosus patients with autoantibodies to Clq and glomerulonephritis. Arthritis Rheum 1999; 42: 1828-32
74. Koene HR, Kleijer M, Swaak AJ, et al. The Fc gammaRIIIA-158F allele is a risk factor for systemic lupus erythematosus. Arthritis Rheum 1998; 41: 1813-8
75. Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcyRIIIa (CD 16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997; 100: 1059-70
76. Edberg JC, Langfeld CD, Wu J, et al. Genetic linkage and association of Fcã receptor IIIA (CD16A) on chromosome 1q23 with human systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2132-40
77. Kyogoku C, Dijstelbloem HM, Tsuchiya N, et al. Fc gamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum 2002; 46: 1242-54
78. Moser KL, Ncas BR, Salmon JE, et al. Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome Iq in African-American pedigrees. Proc Natl Acad Sci U S A 1998; 95: 14869-74
79. Eskdale J, Gallagher G, Verweij CL, et al. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A 1998; 95: 9465-70
80. Mehrian R, Quismorio FP, Strassmann G, et al. Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus. Arthritis Rheum 1998; 41: 596-602
81. Mok CC, Lanchbury JS, Chan DW, et al. Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum 1998; 41: 1090-5
82. Lazarus M, Hajeer AH, Turner D, et al. Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. J Rheumatol 1997; 24: 2314-7
83. Huang CM, Wu MC, Wu JY, et al. Asssociation of vitamin D receptor gene BsmI polymorphisms in Chinese patients with systemic lupus erythematosus. Lupus 2002; 11: 31-4
84. Ozaki Y, Nomura S, Nagahama M, et al. Vitamin-D receptor genotype and renal disorder in Japanes patients with systemic lupus erythematosus. Nephron 2000; 85: 86-91
85. Tassiulas IO, Aksentijevich I, Salmon JE, et al. Angiotensin I converting enzyme gene polymorphisms in systemic lupus erythematosus: decreased prevalence of DD genotype in African American patients. Clin Nephrol 1998; 50: 8-13
86. Sato H, Akai Y, Iwano M, et al. Association of an insertion polymorphism of angiotensin-converting enzyme gene with the activity of systemic lupus erythematosus. Lupus 1998; 7: 530-4
87. Akai Y, Sato H, Iwano M, et al. Association of an insertion polymorphism of angiotensin-converting enzyme gene with the activity of lupus nephritis. Clin Nephrology 1999; 51: 141-6
88. Pullmann Jr R, Lukac J, Skerenova M, et al. Association between systemic lupus erythematosus and insertion/deletion polymorphism of the angiotensin converting enzyme (ACE) gene. Clin Exp Rheumatol 1999; 17: 593-6
89. Molad Y, Gal E, Magal N, et al. Renal outcome and vascular morbidity in systemic lupus erythematosus (SLE): lack of association with the angiotensin-converting enzyme gene polymorphism. Semin Arthritis Rheum 2000; 30: 132-7
90. Kaufman KM, Kelly J, Gray-McGuire C, et al. Linkage analysis of angiotensin-converting enzyme (ACE) insertion/deletion polymorphism and systemic lupus erythematosus. Mol Cell Enocrinol 2001; 177: 81-5
91. Matsushita M, Tsuchiya N, Shiota M, et al. Lack of a strong association of CTLA-4 exon 1 polymorphism with the susceptibility to rheumatoid arthritis and systemic lupus erythematosus in Japanese: an association study using a novel variation screening method. Tissue Antigens 1999; 54: 578-84
92. Tsao BP. The genetics of human lupus. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. Philadelphia (PA): Lippincott Williams and Wilkins, 2002: 97-120
93. Kammer GM, Perl A, Richardson BC, et al. Abnormal T cell signal transduction in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 1139-54
94. Prokunina L, Castillejo-Lopez C, Oberg F, et al. A regulatory polymorphism in PDCD1 is associated with susceptibitity to systemic lupus erythematosus in humans. Nat Genet 2002; 32: 666-9
95. Tsao BP, Cantor RM, Kalunian KC, et al. Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. J Clin Invest 1997; 99: 725-31
96. Lindqvist AK, Steinsson K, Johanneson B, et al. A susceptibility locus for human systemic lupus erythematosus (hSLE1) on chromosome 2q. J Autoimmun 2000; 14: 169-78
97. Gray-McCuire C, Moser KL, Gaffney PM, et al. Genome scan of human systemic lupus erythematosus by regression modeling: evidence of linkage and epistasis at 4p16-15.2. Am J Hum Genet 2000; 67: 1460-9
98. Gaffney PM, Kearns CM, Shark KB, et al. A genome-wide search for susceptibility genes in human systemic lupus erythematosus sib-pair families. Proc Natl Acad Sci U S A 1998; 95: 14875-9
99. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-29
100. Tsao BP, Cantor RM, Grossman M, et al. PARP alleles within the linked chromosomal region are associated with systemic lupus erythematosus. J Clin Invest 1999; 103: 1135-40
101. Boorboor P, Drescher BE, Hartung K, et al. Poly(ADP-ribose) polymerase polymorphisms are not a genetic risk factor for systemic lupus erythematosus in German Caucasians [letter]. J Rheumatol 2000; 27: 2061
102. Criswell LA, Moser KL, Gaffney PM, et al. PARP alleles and SLE: failure to confirm association with disease susceptibility. J Clin Invest 2000; 105: 1501-2
103. Risch N. Searching for genes in complex diseases: lessons from systemic lupus erythematosus. J Clin Invest 2000; 105: 1503-6
104. Scofield RH, Bruner GR, Kelly JA, et al. Thrombocytopenia identifies a severe familial phenotype of systemic lupus erythematosus and reveals genetic linkages at 1q22 and 11p13. Blood 2003 Feb 1; 101 (3): 992-7
105. Kelly J, Thompson K, Kilpatrick J, et al. Evidence for a susceptibility gene (SLEH1) on chromosome 11q14 for systemic lupus erythematosus (SLE) families with hemolytic anemia. Proc Natl Acad Sci U S A 2002; 99: 11766-71
106. Namjou B, Nath SK, Kilpatrick J, et al. Stratification of pedigrees multiplex for systemic lupus erythematosus and for self-reported rheumatoid arthritis detects a systemic lupus erythematosus susceptibility gene (SLER1) at 5p15.3. Arthritis Rheum 2002; 46: 2937-45
107. Tsao BP, Grossman JM, Riekmekasten G, et al. Familiarity and Co-occurence of clinical features of systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2678-85
108. Namjou B, Nath S, Kilpatrick J, et al. Genome scan stratified by the presence of anti-double-stranded DNA (dsDNA) autoantibody in pedigrees multiplex for systemic lupus erythematosus (SLE) establishes linkages at 19p13.2 (SLED1) and 18q21.1 (SLED2). Genes Immun 2002; 3 Suppl. 1: S35-4
109. Quintero-Del-Rio AI, Kelly JA, Kilpatrick J, et al. The genetics of systemic lupus erythematosus stratified by renal disease: linkage at 10q22.3 (SLEN1), 2q34-35 (SLEN2), and 11p15.6 (SLEN3). Genes Immun 2002; 3 Suppl. 1: S57-62
110. Tsao BP, Cantor RM, Grossman JM, et al. Linkage and interaction of loci on 1q23 and 16q12 may contribute to susceptibility to systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2928-36
111. Tsokos GC, Neprom GT. Gene therapy in the treatment of autoimmune diseases. J Clin Invest 2000; 106: 181-3
112. Tsokos GC, Kovacs F, Sfikakis PP, et al. Defective antigen presenting cell function in patients with systemic lupus erythematosus: Role of the B7/BB1(CD80) costimulatory molecule. Arthritis Rheum 1996; 39: 600-9
113. Via CS, Tsokos GC, Bermas B, et al. Multiple T cell-antigen presenting cell interactions in human systemic lupus erythematosus. Evidence for heterogeneous expression of multiple defects. J Immunol 1993; 151: 3914-22
114. Iliopoulos AG, Tsokos GC. Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin Arthritis Rheum 1996; 25: 318-36
115. Herndon TM, Juang Y-T, Solomou E, et al. Electroporation-mediated gene transfer of p65 into T lymphocytes from systemic lupus erythematosus patients leads to increased levels of interleukin-2 promoter activity. Clin Immunol 2002; 103: 145-53
116. Tenbrock K, Juang Y-T, Gourley MF, et al. Antisense cyclic adenosine 5′-monophosphate response element modulator up-regulates IL-2 in T cells from patients with systemic lupus erythematosus. J Immunol 2002; 169: 4147-52